Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax maintenance with or without low-dose cytarabine for AML in first complete remission
ACTRN12619000280101Phase 2Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Venetoclax + low-dose cytarabine, Venetoclax monotherapy and Standard of care observation (3 arms). Primary endpoint: Failure-free survival. Started Jul 2020; status: terminated.
02
Drugs
venetoclaxcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12619000280101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000280101.